Drugs / VRN110755
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07141381 | Aug → Dec 2025 | — | Voronoi, Inc | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07699328 | Mar 2024 → Jan 2029 expected | non-small cell lung carcinoma | Voronoi, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRN110755 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07699328 ↗ |
| Action | Inhibit | “VRN110755 is an investigational EGFR inhibitor administered as an 80 mg oral capsule.” NCT07141381 ↗ |
| Route | Oral | “VRN110755 is an investigational EGFR inhibitor administered as an 80 mg oral capsule.” NCT07141381 ↗ |
| Target | EGFR | “VRN110755 is an investigational EGFR inhibitor administered as an 80 mg oral capsule.” NCT07141381 ↗ |